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Abstract: The main driver behind biofilm research is the desire to understand the mechanisms
governing the antibiotic tolerance of biofilm-growing bacteria found in chronic bacterial infections.
Rather than genetic traits, several physical and chemical traits of the biofilm have been shown
to be attributable to antibiotic tolerance. During infection, bacteria in biofilms exhibit slow
growth and a low metabolic state due to O2 limitation imposed by intense O2 consumption of
polymorphonuclear leukocytes or metabolically active bacteria in the biofilm periphery. Due to
variable O2 availability throughout the infection, pathogen growth can involve aerobic, microaerobic
and anaerobic metabolism. This has serious implications for the antibiotic treatment of infections
(e.g., in chronic wounds or in the chronic lung infection of cystic fibrosis patients), as antibiotics
are usually optimized for aerobic, fast-growing bacteria. This review summarizes knowledge
about the links between the microenvironment of biofilms in chronic infections and their tolerance
against antibiotics.
Keywords: biofilm; microenvironmental; antibiotic tolerance
1. Introduction
In medical microbiology, the clinical implications of bacterial biofilms are particularly pronounced
in chronic infections [1]. Biofilms in chronic infections can be either surface associated or suspended [2].
Surface-associated biofilms are found in a number of cases, such as on teeth [3] or in implant-associated
infections [4–6] where bacteria reside on the surface of, for example, an indwelling catheter [7,8].
Such surface colonization of pathogens forms large biofilms of up to 1200 µm in thickness [9].
In contrast, chronic lung infection in cystic fibrosis (CF) patients [9,10], chronic wounds [9], soft tissue
filler-related infections [11,12], and chronic middle-ear infections [13,14] carry biofilms as non-attached,
relatively small, suspended cell aggregates (~2–200 µm in diameter) [9,10,15–17]. Such suspended
biofilms are typically embedded in a secondary matrix that consists of pus, wound-bed sludge or
CF mucus, and the bacterial cell aggregates are often surrounded by inflammatory cells such as
polymorphonuclear leukocytes (PMNs) [10,18,19] (Figure 1).
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Figure 1. Confocal laser-scanning microscopy micrography of ex vivo lung tissue from a P. aeruginosa-
infected CF patient. Tissue was stained with peptide nucleic acid fluorescence in situ hybridization 
(PNA-FISH) probes specific for P. aeruginosa with a red Texas-Red flourophor and counterstained 
with blue (4′,6-diamidino-2-phenylindole) DAPI for eukaryotic nucleus. 630×. [19]. 
The advent of antibiotics following the discovery of penicillin by Alexander Fleming in 1929 was 
a major breakthrough in the treatment of bacterial infections, which were a major cause of morbidity 
and mortality in the general population. However, resistance to antibiotics was already reported in 
the 1940s [20] and has been increasing ever since. Resistance to antibiotics is caused by inherited or 
acquired genetic changes via mutations or genetic transfer between bacteria [21,22] such as that 
caused by efflux pumps, which are transport proteins involved in the extrusion of toxic substrates 
[23]. Antibiotic resistance continues to receive much attention, but it should not be confused with 
antibiotic tolerance. Whereas resistance is an irreversible change to the genome of the bacteria, 
tolerance is a reversible state of the bacteria that enables them to survive antibiotic treatment [24]. 
When antibiotic therapy fails [25–27] an infection can become chronic due to several factors 
inherent to biofilm-growing bacteria. Høiby et al. (2010) describes chronic bacterial infections, 
including foreign-body infections, as infections, (i) that persist despite antibiotic therapy and the 
innate and adaptive immune and inflammatory responses of the host, and (ii) that are characterized, 
in contrast to colonization, by an immune response and persisting pathology [28]. In comparison to 
acute bacterial infections, chronic infections are described by slow progression and low-grade 
pathogenesis. Chronic bacterial infections can develop if the main defensive system is impaired. Such 
impairments include the disruption of the anatomical barrier (for example, skin or mucosal 
membranes) or deficiencies in the innate immune response (i.e., macrophages or neutrophils) which 
allow bacteria that would otherwise be rapidly cleared by the host to establish a chronic infection 
[29]. The deficiencies can be either congenital (for example, cystic fibrosis (CF)), acquired (for 
example, diabetes), or due to the presence of foreign-body implants [9,30]. Why some bacterial 
infections manage to establish chronic infections, which are difficult if not impossible to resolve, 
remains largely unanswered. However, increasing evidence points towards biofilm-growing bacteria 
as common denominators behind chronic infections [2].  
  
Figure 1. Confocal laser-scanning microscopy micrography of ex vivo lung tissue from a
P. aeruginosa-infected CF patient. Tissue was stained with peptide nucleic acid fluorescence in situ
hybridization (PNA-FISH) probes specific for P. aeruginosa with a red Texas-Red flourophor and
counterstained with blue (4′,6-diamidino-2-phenylindole) DAPI for eukaryotic nucleus. 630×. [19].
The advent of antibiotics following the discovery of penicillin by Alexander Fleming in 1929 was
a major breakthrough in the treatment of bacterial infections, which were a major cause of morbidity
and mortality in the general population. However, resistance to antibiotics was already reported in
the 1940s [20] and has been increasing ever since. Resistance to antibiotics is caused by inherited
or acquired genetic changes via mutations or genetic transfer between bacteria [21,22] such as that
caused by efflux pumps, which are transport proteins involved in the extrusion of toxic substrates [23].
Antibiotic resistance continues to receive much attention, but it should not be confused with antibiotic
tolerance. Whereas resistance is an irreversible change to the genome of the bacteria, tolerance is a
reversible state of the bacteria that enables them to survive antibiotic treatment [24].
When antibiotic therapy fails [25–27] an infection can become chronic due to several factors
inherent to biofilm-growing bacteria. Høiby et al. (2010) describes chronic bacterial infections,
including foreign-body infections, as infections, (i) that persist despite antibiotic therapy and the
innate and adaptive immune and inflammatory responses of the host, and (ii) that are characterized,
in contrast to colonization, by an immune response and persisting pathology [28]. In comparison
to acute bacterial infections, chronic infections are described by slow progression and low-grade
pathogenesis. Chronic bacterial infections can develop if the main defensive system is impaired.
Such impairments include the disruption of the anatomical barrier (for example, skin or mucosal
membranes) or deficiencies in the innate immune response (i.e., macrophages or neutrophils) which
allow bacteria that would otherwise be rapidly cleared by the host to establish a chronic infection [29].
The deficiencies can be either congenital (for example, cystic fibrosis (CF)), acquired (for example,
diabetes), or due to the presence of foreign-body implants [9,30]. Why some bacterial infections
manage to establish chronic infections, which are difficult if not impossible to resolve, remains largely
unanswered. However, increasing evidence points towards biofilm-growing bacteria as common
denominators behind chronic infections [2].
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When examining the literature on the lifestyle of bacteria living biofilms, one aspect is
often repeated: slow growth and low metabolic state [2,19,31–34]. Biofilm-embedded bacteria in
slow-growing or even in dormant states in infections will have profound effect on the effectiveness of
antibiotics [35–37]. Stratified growth patterns in infectious biofilms may point towards a scheme in
which growth conditions have a key influence on the antibiotic tolerance exhibited by cells with low
growth rates. This makes it paramount to shed light on the microenvironment surrounding bacterial
biofilms in chronic infections.
2. The Microenvironment of Chronic Biofilm Infections
While different chronic bacterial infections throughout the human body may appear diverse,
they share several similarities in terms of the characteristic growth pattern and microenvironment of
the pathogenic bacteria. Many chronic bacterial infections thus exhibit the presence of small suspended
biofilm aggregates surrounded by a high-density of inflammatory cells and imbedded in pus or tissue,
which present an hypoxic or anoxic habitat [9,38]. Chronic lung infections in CF patients present a
well-explored example of such conditions.
An adult at rest inhales about 11,000 liters of air every day (~0.5 liters air per breath, 15 breaths per
minute); however, anoxic zones in the lungs of CF patients can still be found. A combination of oxygen
(O2) consumption by epithelial cells [17]—with excessive O2 consumption by active PMNs engaged in
the respiratory burst or production of nitric oxide (NO) directed against bacteria [39,40]—can lead to
the development of hypoxic and anoxic conditions in CF lungs [17]. Furthermore, ex vivo samples
of lungs from CF patients have revealed that the number of PMNs surrounding bacterial biofilms
correlates negatively with the growth rate of P. aeruginosa [19]. As PMNs consume O2, these biofilms
may experience strong O2 limitation, thereby rendering them less susceptible to antibiotic treatment.
Reduced growth rates under hypoxia or anoxia in biofilms associated with chronic infections can have
serious implications, as antibacterial treatment strategies are usually developed for aerobic bacteria [26].
The ability of the PMN response to impose slow bacterial growth is further supported by recent
findings, showing that Stenotrophomonas maltophilia, Staphylococcus aureus, Achromobacter xylosoxidans
and Streptococcus pneumonia also grow very slowly in the CF sputum [41,42].
Few O2 measurements have been performed in situ in the CF lung [17] and in ex vivo sputum
samples [40,43], and such measurements have revealed steep O2 gradients in the mucus constituting
a secondary matrix of bacterial aggregates. This is further supported by in vivo observations of the
upregulation of the global, O2-sensing, anaerobic regulator Anr-controlled genes of P. aeruginosa in CF
sputum [38,44,45]. Although it is possible to measure O2 gradients in the first two to three branches of
the bronchia, many low-O2 niches may exist on an even smaller scale than is currently measurable
in vivo. Thus, an appropriate description of the microenvironment encountered by bacteria in chronic
infections requires further analysis, as relatively small niches may represent large physical and chemical
differences for the inhabiting bacteria (Figure 2). Altogether, the bacteria inhabiting chronic infections
are faced with very variable environments that favor versatile metabolism and physiology and may
strongly influence the growth and in turn the effectiveness of antibiotics. Kopf et al. show a very slow
(median of 2.1 days per cells division) but extremely diverse growth rate even at the single-cell level for
S. aureus in freshly harvested expectorates from a patient with CF [42]. At present, in vivo observations
suggest that the availability of O2 or alternative electron acceptors is a core limiting factor for bacterial
biofilm growth in chronic infections [19]. It is therefore vital that researchers and clinicians understand
how bacterial metabolism can adjust to the accessibility of electron acceptors from fully oxic to anoxic
conditions if we are to comprehend the development of antibiotic tolerance in chronic biofilm infections.
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Figure 2. Schematic drawing of a biofilm-infected bronchial lumen based on ex vivo observation 
(Figure 1). (A) The bronchial lumen with two non-attached biofilms surrounded by polymorph 
nuclear leukocyte (PMN) infiltrated mucus; (B) oxygen gradient through the mucus towards the 
biofilm. High concentration of PMNs results in steeper oxygen gradients due to high consumption; 
(C) high concentration of PMNs around a biofilm results in slow-growing bacteria within the biofilm. 
Lesser concentration results in increased growth due to improved accessibility to oxygen; (D) 
differences in growth rate may result in differentiated tolerance towards antibiotics. Jensen et al. [46]. 
2.1. Aerobic Respiration 
Aerobic respiration is the most energy-efficient form of respiration [47,48]: approximately 50% 
of the potential energy in the electron donor is conserved in the form of an ATP-generating proton-
motive force [49]. The machinery for aerobic respiration consists of NADH dehydrogenase (Complex 
I), the quinone pool (UQ), the bc1 complex (Complex III), and cytochrome c (Cyt. c). Aerobic 
respiration requires terminal oxidases (Complex IV). For example, P. aeruginosa has five terminal 
oxidases that catalyze the four-electron reduction of molecular O2 to water; they differ in their affinity 
for O2, the efficiency of energy coupling, and the tolerance to various stresses where the high-affinity 
terminal oxidases are used under hypoxic conditions [49]. The bo3 oxidase (cyo) and the cyanide-
insensitive oxidase (CIO) (cio) are quinol oxidases, whereas cbb3-1 (cco1), cbb3-2 (cco2) and aa3 (cox) are 
cytochrome c oxidases [48,50].  
  
Figure 2. Sche atic dra ing of a biofil -infected bronchial lu en based on ex vivo observation
(Figure 1). (A) The bronchial lu en ith t o non-attached biofil s surrounded by poly orph
nuclear leukocyte (PMN) infiltrated mucus; (B) oxygen gradient through the mucus towards
the biofilm. High concentration of PMNs results in steeper oxygen gradients due to high
consumption; (C) high concentration of PMNs around a biofilm results in slow-growing bacteria
within the biofilm. Lesser concentration results in increased growth due to improved accessibility
to oxygen; (D) differences in growth rate may result in differentiated tolerance towards antibiotics.
Jensen et al. [46].
2.1. Aerobic Respiration
Aerobic respiration is the most energy-efficient form of respiration [47,48]: approximately 50% of
the potential energy in the electron donor is conserved in the form of an ATP-generating proton- otive
force [49]. The machinery for aerobic respiration consists of NADH dehydrogenase (Complex I),
the quinone pool (UQ), the bc1 complex ( o plex III), and cytochrome c (Cyt. c). Aerobic respiration
requires terminal oxidases (Complex IV). For example, P. aeruginosa has five terminal oxidases that
catalyze the four-electron reduction of molecular O2 to water; they differ in their affinity for O2,
the efficiency of energy coupling, and the tolerance to various stresses where the high-affinity terminal
oxidases are used under hypoxic conditions [49]. The bo3 oxidase (cyo) and the cyanide-insensitive
oxidase (CIO) (cio) are quinol oxidases, whereas cbb3-1 (cco1), cbb3-2 (cco2) and aa3 (cox) are cytochrome
c oxidases [48,50].
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2.2. Anaerobic Respiration
While O2 is the most energy-efficient electron acceptor, P. aeruginosa and many other bacteria
can use other electron acceptors for respiration. Among these, nitrate (NO3−) respiration has an
energy yield approaching that of O2 [49]. Anaerobic respiration by denitrification, where NO3− is
reduced to gases [51], is able to conserve only ~30% [49] of the potential energy of an electron donor
for ATP-generation due to a possible loss of energy during the denitrification pathway. NO3− is
common in the environment and available in vivo [40,52,53] at physiological levels supporting
growth [54]. PMNs are abundant in CF lungs and are reported to contribute NO3− or nitrogen dioxide
(NO2−) [55]. Reduction of NO3− to NO2− is a prerequisite to actual denitrification, where NOx are
reduced to gases [51]. Denitrification relies on the same respiratory framework as aerobic respiration.
All denitrifiers can respire aerobically, but specific enzymes are needed for denitrification [49].
P. aeruginosa has a complete set of denitrification enzymes that reduce NO3− to N2 (nitrogen gas) [51],
and show in Figure 3:
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(O2−) by PMNs—combined with endogenously produced nitric oxide by nitric-oxide synthases in 
lung tissue and PMNs—may result in the formation of peroxynitrite, which can decompose into NO3− 
[56]. This is supported by observations of reduced exhaled NO from CF lungs [57]. Because of ROS 
production—and to a lesser extent because of the production of NO by the activated PMNs—hypoxic 
and anoxic zones are created in which aerobic respiration is limited due to the lack of O2 as an electron 
acceptor. However, the combination of ROS and NO production may alleviate the consequences 
associated with the limitation of aerobic respiration by the simultaneous production of NO3−, which 
may serve as an alternative electron acceptor, thereby allowing for ATP generation by anaerobic 
respiration [55]. The physiological concentration of NO3− in CF lungs can reach up to 1 mM, as 
estimated from concentrations of NO3− measured in freshly expectorated CF sputum [40,52,53]. The 
reported concentrations are based on bulk measurements. However, due to the highly varied spatio-
temporal distribution of electron acceptors involved in respiration (e.g., O2 and N2O [40,43]), local 
NO3− concentrations may be even higher. NO3− concentrations as high as 100 mM have been shown 
to yield high bacterial densities in CF lungs [58,59]. However, physiologically relevant growth rates 
can be obtained by supplementing anoxic cultures of P. aeruginosa with far less than 1 mM NO3− [54]. 
Similar to the CF environment, microsensor measurements of O2-concentration profiles in ex vivo 
chronic human wounds and in vivo chronic mouse wounds reveal steep O2 gradients [60]. 
Furthermore, anaerobic bacteria have been isolated from both expectorated CF mucus [61–63] and 
chronic wounds [64,65], thereby indicating the existence of hypoxic and anoxic zones.  
2.3. Substrate Level Phosphorylation 
High levels of amino acids are present in CF sputum [66], and P. aeruginosa is able to utilize such 
amino acids as growth substrate in CF sputum [67]. P. aeruginosa can ferment arginine anaerobically 
such that arginine is degraded to ornithine, which generates 1 mol ATP from 1 mol arginine [68]. In 
comparison, the oxidation of 1 molecule of glucose can generate 36 molecules of ATP during aerobic 
respiration [69]. In contrast, fermentation of the Alfa-keto acid pyruvate does not supply P. aeruginosa 
with energy for growth, but it does enable the long-term survival of the bacterium [70,71], again 
adding to the remarkable persistence of P. aeruginosa in chronic infections.  
  
Figure 3. Denitrification enzymes that reduce NO3− to N2 (nitrogen gas).
The primary CF pathogen, P. aeruginosa, can survive during O2 limitation by performing anaerobic
respiration with NO3−. The production of the reactive oxygen species (ROS) superoxide (O2−) by
PMNs—combined with endogenously produced nitric oxide by nitric-oxide synthases in lung tissue
and PMNs—may result in the formation of peroxynitrite, which can decompose into NO3− [56].
This is supported by observations of reduced exhaled NO from CF lungs [57]. Because of ROS
production—and to a lesser extent because of the production of NO by the activated PMNs—hypoxic
and anoxic zones are created in which aerobic respiration is limited due to the lack of O2 as an electron
acceptor. However, the combination of ROS and NO production may alleviate the consequences
associated with the limitation of aerobic respiration by the simultaneous production of NO3−, which
may serve as an alternative electron acceptor, thereby allowing for ATP generation by anaerobic
respiration [55]. The physiological concentration of 3 in CF lungs can reach up to 1 mM,
as estimated from concentrations of NO3− measured in freshly expectorated CF sputum [40,52,53].
The reported concentrations are based on bulk measurements. However, due to the highly varied
spatio-temporal distribution of electron acceptors involved in respiration (e.g., O2 and N2O [40,43]),
local NO3− concentrations may be even higher. NO3− concentrations as high as 100 mM have been
shown to yield high bacterial densities in CF lungs [58,59]. However, physiologically relevant growth
rates can be obtained by supplementing anoxic cultures of P. aeruginosa with far less than 1 mM
NO3− [54]. Similar to the CF environment, microsensor easurements of O2-concentration profiles
in ex vivo chronic human wounds and in vivo chronic mouse wounds reveal steep 2 gradients [60].
Furthermore, anaerobic bacteria have been isolated from both expectorated CF mucus [61–63] and
chronic wounds [64,65], thereby indicating the existence of hypoxic and anoxic zones.
2.3. Substrate Lev l Phosphorylation
High levels of amino acids are pres nt in CF sput m [66], and P. aeruginosa is able to utilize such
amino acids as growth substrate in CF sput m [67]. P. aeruginosa can ferment argin e anaerobically
such that arginine is degraded to ornithine, ic l fr 1 mol arginine [68].
In co paris , t l f l cose can generate 36 molecules of ATP during aerobic
respiration [69]. In contrast, fermenta ion of the Alfa-keto acid pyruvate does not sup ly P. aeruginosa
with en rgy for growth, but it does enabl the long-term survival of the bacterium [70,71], again adding
to the remarkabl persistence of P. aeruginosa in chronic i fections.
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2.4. Microaerobic Metabolism
Microaerobic metabolism is not very well defined, but it may be described as an intermediate
state in which the organism(s) simultaneously performs aerobic and anaerobic respiration or
fermentation [72].
During hypoxic conditions, some microorganisms can perform so-called aerobic denitrification.
Aerobic denitrification, or co-respiration of O2 and NO3−, was reviewed by Robertson and Kuenen
and can be described as NO3− respiration in the presence of O2 [73]. According to phylogenetic
analysis, aerobic denitrifiers mainly belong to α-, β- and γ-Proteobacteria [74]. Alvarez-Ortega et al. [59]
report that P. aeruginosa expresses overlapping gene sets depending on O2 concentration, and moreover
that low O2 triggers denitrification genes. P. aeruginosa can thus switch flexibly between several
types of electron acceptors [59]. This is consistent with cbb3-1 being constitutively expressed [48],
thereby enabling P. aeruginosa to adapt to variable levels of O2. Diverse chemical microniches may exist
in close proximity within the same infection [19]. This complicates the treatment of chronic biofilm
infections, as the bacteria do not exhibit a homogeneous physiological state but grow under a variety
of conditions, probably resulting in varying growth rates.
3. Correlating the Microenvironment to Antibiotic Tolerance
One of the main targets for biofilm research has been the desire to understand the mechanisms
behind tolerance towards antibiotics. The explanation for this enhanced tolerance is attributable to
several physical and chemical traits of the biofilm, which enable bacteria to survive very high doses of
antibiotics, usually exceeding the minimal inhibitory concentration (MIC) of the antibiotic many times.
In fact, it has been reported that the MIC of biofilm-growing bacteria can be 100–1000 times higher
than that of its planktonic counterpart [75–77]. Traditionally, MIC is determined by exposing bacteria
to increasing concentrations of antibiotics and observing the level at which growth is inhibited [78,79].
However, MIC measured in vitro depends on growth conditions [24], thereby making it difficult to
transfer such findings to in vivo settings. Furthermore, MIC is typically determined in a planktonic
bacterial suspension, which does not represent the in vivo scenario in chronic infections, where
biofilm-growing bacteria predominate [2]. However, in 1999, the first method for estimating the MBEC
(minimal biofilm-eradication concentrations) growing on a surface was reported by Ceri et al. who
used a Calgary Biofilm device (CBD) [80]. Since then, other methods, such as bioreactor-based models
and flow cells systems, and definitions such as minimal biofilm inhibitory concentration have been
reported, but a standardization of the procedures remains outstanding [27].
The matrix of the biofilm itself can be considered a physical barrier by conferring poor penetration
of antibiotics, but several studies speculate that this is probably not a universal mechanism [32,81].
There is experimental evidence that negatively charged eDNA and several polysaccharide components
of a biofilm matrix may contribute to shielding against positively charged aminoglycosides [82,83].
Additionally, studies have found indications of a genetic contribution to increased antimicrobial
tolerance [84]. For example, consider efflux pumps [85], toxin-antitoxin modules [86], quorum
sensing [87], modifying the charge of the cell surface [88], and active adaptation of expression as
a response to nutrient limitation [89,90]. We note that genetic tolerance could play a role during biofilm
growth, but we argue that within chronic infection in the physiological microenvironment may have a
strong influence on the development of tolerance.
From in vitro biofilm studies, we know that chemical heterogeneity can protect the biofilm
from antibiotics [91,92]. In in vitro, surface-associated biofilms, thick P. aeruginosa biofilms harbor
physiologically different subpopulations. Bacteria at the top of the biofilm are metabolically
active—as determined by mRNA levels and selective green-fluorescence-protein (GFP) labelling
of active bacterial cells—whereas biofilms at the bottom of the biofilm experience reduced growth rates
and low mRNA levels [33]. Slow growth rates coincide with increased tolerance towards tobramycin
and ciprofloxacin, whereas metabolically active bacterial cells are more susceptible [92]. The increased
antibiotic tolerance of biofilms has been the focus of several studies, which have drawn various
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conclusions. Spoering et al. argue that the increased tolerance of biofilm bacteria towards antibiotics,
as compared to planktonic bacteria, could be attributed to their reduced growth, and that biofilm
bacteria and stationary-phase planktonic bacteria are equally tolerant to antibiotics [93]. On the other
hand, Staudinger et al. [94] suggest that cell-aggregate formation, rather than the biofilm phenotype,
is responsible for increased antibiotic and host-defense tolerance. Mikkelsen et al. [95] also question
whether biofilms and planktonic bacterial cells are phenotypically different entities and observe that
biofilm protein profiles resemble that of planktonic cells. They may simply represent different growth
phases [95]. Furthermore, in P. aeruginosa biofilms, O2 limitation, and thus low metabolic activity,
can be correlated with increased antibiotic tolerance [32,96]. Recently, Pabst et al. found that a similar
pattern of local hypoxia and reduced growth rates affect the antibiotic tolerance of S. aureus [81].
The ability of P. aeruginosa to grow under O2 limitation, and its ability to utilize arginine and
NO3− during these conditions, for example, has several implications for antibiotic susceptibility.
Tobramycin targets O2-dependent active transport, and its action should thus be inhibited during
O2 limitation. However, in anoxic biofilm, the addition of an alternative electron acceptor such as
NO3− or arginine for fermentation [96,97] increases susceptibility to tobramycin, thereby indicating
that the anti-bacterial activity of tobramycin also targets anaerobic metabolism to some degree. In fact,
according to Borriello et al., O2 limitation could account for 62% of Ciprofloxacin tolerance, 69% of
Tobramycin tolerance, 80% of Tetracycline tolerance and >110% in the case of Ceftazidime [96].
Furthermore, Connell et al. show that in vitro tolerance towards antibiotics already occurs in aggregates
of just 100 bacteria, which is not enough to create anoxia inside the biofilm [98]. This indicates that
O2 limitation is an important, but probably not the only, factor contributing to antibiotic tolerance
in P. aeruginosa. Perhaps the low bacterial metabolism in anoxic regions contributes equally to
the observed antibiotic tolerance of biofilms in vitro and in vivo. It has thus been suggested that
stimulation of bacterial activity by supplementation of NO3− or arginine could lead to increased
susceptibility to tobramycin and ciprofloxacin when treating in vivo biofilms [97].
The fact that biofilm tolerance towards antibiotics is primarily attributable to a physico-chemical,
rather than to a genetic trait is supported by studies showing that tolerance to antibiotics is
reversible in vitro [11,99,100]. Antibiotic susceptibility can be restored if bacteria are released
from biofilms [32,101] or if metabolism is activated by stimulating aerobic respiration, anaerobic
respiration, or substrate-level phosphorylation in biofilm [97,102,103]. This aspect has been further
demonstrated in a study, where transcriptional analysis has revealed a correlation between the
genetic expression of planktonic growing bacteria and alginate-encapsulated, biofilm-growing bacteria
supplemented with an alternative electron acceptor (NO3−) [44]. When the biofilm-growing bacteria
were supplemented with NO3−, electron acceptor limitation was alleviated, thereby stimulating
metabolism. When the alginate-encapsulated biofilm-growing bacteria were not supplemented with
NO3−, the bacteria experienced electron-acceptor limitation, and the genetic-expression profile was
very different from that of the planktonic-growing bacteria [44]. This suggests that it was the alleviation
of electron-acceptor limitation—and thus stimulated metabolism rather than the biofilm-growing state
of the bacteria—that affected the expression profiles. In fact, in vitro studies have shown that such
alleviation of electron-acceptor limitation, which increases metabolism, in turn increases susceptibility
towards the antibiotic tobramycin and ciprofloxacin [97,102,103]. This is in accordance with the fact
that tobramycin and ciprofloxacin are antibiotics that target fast-growing bacteria [104,105]. In other
words, the low metabolism of slow-growing bacteria antagonizes the effect of tobramycin.
4. Treatments to Tackle the Broad Spectrum of Growth Rate
Monotherapy with antibiotics (such as β-lactams and the aminoglycoside tobramycin) is effective
only against active bacterial cells [76]. Due to the nature of chronic infections, treatment with single
antibiotics is not effective, and several classes of antibiotics are often used in a combination to
target bacteria in different metabolic states [2]. An example is the treatment of CF patients, where
a combination of colistin and either ciprofloxacin or tobramycin is used. These combinations target
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different subpopulations of in vitro biofilms, as described below. While tobramycin and ciprofloxacin
target bacteria in the outer active biofilm layer, colistin targets less active or dormant bacteria in the
inner parts of biofilms [37,106].
Another promising approach is to supply extra O2 to hypoxic environments [41,107,108]
to overcome the antibiotic tolerance in established biofilms where dormant bacteria are present.
Hyperbaric O2 treatment (HBOT) has previously been used as an adjuvant to ciprofloxacin on
P. aeruginosa [109,110], but the underlying mechanism still needs to be investigated thoroughly.
Application of HBOT has been shown to enhance the bactericidal activity of tobramycin to S. aureus in
an endocarditis model [107], while ciprofloxacin has been shown to enhance the bactericidal activity in
a P. aeruginosa biofilm model [41,108]. Kolpen et al. recently demonstrated that application of HBOT
during ciprofloxacin treatment is accompanied by indications of restored aerobic bacterial respiration
when hypoxia is established from hyperoxia after clinically relevant durations of HBOT [108].
This forced metabolic shift from anaerobic to aerobic respiration promotes the faster growth of
P. aeruginosa under HBOT, as indicated by increased SYTO9 fluorescence intensity and bacterial
aggregate size after HBOT (Figure 4). HBOT can thus be considered an adjuvant that enhances the
activity of bactericidal antibiotics for several sites of biofilm infection (such as chronic lung infection,
wounds, bones and biliary ducts where hypoxic or anoxic conditions are present) [111].
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5. Conclusions
Our current knowledge of chronic biofilm infections does not provide any simple solutions
that allow us to cope with the observed increased antibiotic tolerance. Efficient antibiotics or
treatment regimens which are able to completely clear all biofilms within a well-established chronic
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bacterial infection remain to be identified. In an effort to overcome the antibiotic tolerance in
chronic bacterial infections, it is imperative that researchers and clinicians better understand and
identify the chemical microenvironments that are characteristic of the biofilms encountered in chronic
infections. Limitation of O2 seems a common feature of such microenvironments. This feature
imposes a limitation on bacterial growth and forces cells to employ metabolic strategies other than
aerobic respiration—for example, fermentation or denitrification. Anaerobic metabolism does not
sustain as much growth and exploitation of electron donors as unrestricted aerobic respiration.
These assumptions are supported by the reportedly slow bacterial growth and relatively high amounts
of available nutrients—such as carbohydrates, proteins and fatty acids, which can be used as electron
donors—in most studied chronic infections. Since chronic biofilm infections are as incredibly complex
as they are, we can only touch the tip of the iceberg in explaining how biofilms persist in infections.
However, there are various indications that metabolic activity is the core of antibiotic tolerance in
biofilm infections.
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